Democritus University of Thrace (DUTH)
Συγκριτική μέτρηση επιπέδων αποπτωτικών - αντιαποπτωτικών παραγόντων σε ασθενείς με ιδιοπαθή πνευμονική ίνωση πριν και μετά θεραπεία με ιντερφερόνη-γ και αζαθειοπρίνη - κορτικοστεροειδή
Abstract
dc:descriptionBackground: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung function deterioration, ultimately leading to death. No pharmacological treatment can stabilize the evolution of the disease. Interferon g and azathioprine have been used as therapeutic options. Apoptosis is an important mechanism for the development of the disease. Increased apoptosis of epithelial cells and decreased apoptosis of myofibroblasts is considered to be involved in the pathogenesis of IPF. Pharmacologic agents who modulate apoptosis might be useful for patients with IPF. Aim: The aim of the present study was to compare the effectiveness of treatment with interferon g plus low dose prednisone versus azathioprine plus low dose prednisone in patients with IPF and to investigate whether the two therapeutic options can modulate the cellular apoptotic profile in patients with IPF Materials and methods: 20 newly diagnosed patients with IPF. 10 patients received azathioprine plus prednisone and 12 patients receivedinterferon g plus prednisone for six months. Clinical evaluation, lung function tests, HRCT, bronchoscopy and bronchoalveolar lavage were performed at baseline and after six months of treatment. We analyzed by immunohistochemistry, the expression of the apoptotic markers fas, fas ligand(fasl), bcl-2 and bax in cells obtained from bronchoalveolar lavage fluid. Apoptosis of BALF cells was also evaluated before and after treatment. In order to evaluate the immunohistochemistry results, we applied digital image analysis assay. We used ELISA to measure soluble fas ligand in the supernatant of BALF. Results: All patients were alive after six months of treatment. There was no statistical difference between the two groups regarding clinical deterioration, inflammatory biomarkers as CRP and ESR or BALF sub-populations. There was no difference in radiological evaluation, evaluated by HRCT. BALF alveolar macrophages undergoing apoptosis were significantly less in IPF patients compared to control at baseline. No difference was found in the expression of fas or fas ligand, and bax between IPF and control group. The expression of anti-apoptotic bcl-2 was less in IPF. After six months of treatment, apoptotic alveolar macrophages continued to be less compared to control and there was a trend towards greater decrease in the interferon g group. A concomitant decrease in fas ligand expression was observed. There was no difference in the levels of soluble fas ligand in the BALF before and after treatment. Conclusion: Compared to azathioprine, treatment with interferon g does not offer any therapeutic advantage regarding the clinical course, lung function tests and BALF of patients with IPF. The decreased apoptotic rate of alveolar macrophages of patients with IPF is not associated with decreased expression of apoptosis mediators involved in the external or internal apoptotic pathway. This difference could be involved in the pathogenesis of IPF. Neither azathioprine nor interferon g could effectively modulate apoptosis in IPF. We are in urgent need of new multimodality treatments for IPF.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Drakopanagiotakis, Fotios
- Δρακοπαναγιωτάκης, Φώτιος
Subjects
dc:subject × 16- Ιδιοπαθής πνευμονική ίνωση
- Απόπτωση
- Ιντερφερόνη-γ
- Αζαθειοπρίνη
- Κορτικοστεροειδή
- Idiopathic pulmonary fibrosis (IPF)
- Apoptosis
- Interferon-γ
- Azathioprine
- Corticosteroids
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Clinical Medicine
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/25694